ZA921270B - Peptides for treatment - Google Patents

Peptides for treatment

Info

Publication number
ZA921270B
ZA921270B ZA921270A ZA921270A ZA921270B ZA 921270 B ZA921270 B ZA 921270B ZA 921270 A ZA921270 A ZA 921270A ZA 921270 A ZA921270 A ZA 921270A ZA 921270 B ZA921270 B ZA 921270B
Authority
ZA
South Africa
Prior art keywords
absent
thr
ser
gly
cys
Prior art date
Application number
ZA921270A
Other languages
English (en)
Inventor
Ove Pedersen
Pedersen Ove
D K Macfadden
K Macfadden D
Original Assignee
Carlbiotech Ltd As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carlbiotech Ltd As filed Critical Carlbiotech Ltd As
Publication of ZA921270B publication Critical patent/ZA921270B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA921270A 1991-02-25 1992-02-21 Peptides for treatment ZA921270B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK031991A DK31991D0 (da) 1991-02-25 1991-02-25 Peptid og farmaceutisk praeparat indeholdende et saadant peptid

Publications (1)

Publication Number Publication Date
ZA921270B true ZA921270B (en) 1992-11-25

Family

ID=8092219

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA921270A ZA921270B (en) 1991-02-25 1992-02-21 Peptides for treatment

Country Status (13)

Country Link
US (1) US5763406A (de)
EP (1) EP0573538B1 (de)
JP (1) JP3250804B2 (de)
AT (1) ATE118349T1 (de)
AU (1) AU1377092A (de)
CA (1) CA2101075C (de)
DE (1) DE69201438T2 (de)
DK (2) DK31991D0 (de)
ES (1) ES2070635T3 (de)
GR (1) GR3015888T3 (de)
IE (1) IE69853B1 (de)
WO (1) WO1992014751A1 (de)
ZA (1) ZA921270B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739109A (en) * 1988-12-16 1998-04-14 Advanced Immunit Inc. Method of treating neuroinflammatory degenerative diseases
US5593967A (en) * 1990-08-31 1997-01-14 Warner-Lambert Company Cholecystokinin antagonists, their preparation and therapeutic use
WO1995008338A1 (en) * 1993-09-24 1995-03-30 Peptide Technology Limited Method for the treatment or prevention of eczema/dermatitis
US6458766B1 (en) * 1998-12-15 2002-10-01 The Regents Of The University Of California Halovir, an antiviral marine natural product, and derivatives thereof
US6613507B1 (en) 2000-03-21 2003-09-02 Yu-an Chang Boraadamantane compounds for the treatment of pathogenic viruses and other medical applications
US7374068B2 (en) * 2004-10-08 2008-05-20 Homax Products, Inc. Particulate materials for acoustic texture material
MY159500A (en) * 2009-05-22 2017-01-13 Genocea Biosciences Inc Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
WO2012074881A2 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
WO2013078299A1 (en) 2011-11-23 2013-05-30 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
ES2444299B1 (es) 2012-08-23 2014-12-12 Nutrición Técnica Deportiva, S.L. Uso de un hidrolizado de caseina como agente antiherpético
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ, インコーポレイテッド ヘルペスを処置するための方法および組成物
EP4308170A1 (de) 2021-03-18 2024-01-24 Seagen Inc. Selektive wirkstofffreisetzung aus internalisierten konjugaten biologisch aktiver verbindungen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0190127A1 (de) * 1984-08-10 1986-08-13 MERCK PATENT GmbH Immunotherapeutische polypeptidheilmittel
US4585587A (en) * 1984-10-19 1986-04-29 Northwestern University Antigenic peptide compounds
IT1190433B (it) * 1985-12-11 1988-02-16 Prodotti Antibiotici Spa Peptidi correlati al lisozima
WO1987007614A1 (en) * 1986-06-03 1987-12-17 Pert Candace B Small peptides which inhibit binding to t-4 receptors
ATE96450T1 (de) * 1986-06-03 1993-11-15 Us Commerce Kleine peptide, die die bindung an t-4-rezeptoren inhibieren und als immunogene wirken.
AU1808088A (en) * 1987-05-22 1988-12-21 Syntbiotech, Inc. Synthetic peptides and a method of treating aids
WO1989012067A1 (en) * 1988-05-27 1989-12-14 The United States Of America, As Represented By Th Compositions having use as treatment of psoriasis and neuropsychiatric deficits
DE3841761A1 (de) * 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
GB8905606D0 (en) * 1989-03-11 1989-04-26 Scras Peptides

Also Published As

Publication number Publication date
DK0573538T3 (da) 1995-06-26
DE69201438D1 (en) 1995-03-23
JPH06507386A (ja) 1994-08-25
GR3015888T3 (en) 1995-07-31
US5763406A (en) 1998-06-09
DK31991D0 (da) 1991-02-25
ATE118349T1 (de) 1995-03-15
AU1377092A (en) 1992-09-15
CA2101075C (en) 2003-04-22
EP0573538A1 (de) 1993-12-15
IE920496A1 (en) 1992-08-26
WO1992014751A1 (en) 1992-09-03
CA2101075A1 (en) 1992-08-26
DE69201438T2 (de) 1995-10-05
ES2070635T3 (es) 1995-06-01
EP0573538B1 (de) 1995-02-15
IE69853B1 (en) 1996-10-02
JP3250804B2 (ja) 2002-01-28

Similar Documents

Publication Publication Date Title
ZA921270B (en) Peptides for treatment
EP1077070A3 (de) Orale Darreichungsform
NZ502872A (en) Mevinolin and compaction as LFA-1 antagonists for treating autoimmune diseases
MD1652F2 (en) Protein possessing the cytokin - type activity, recombinant DNA-codifyer for such protein, transformed cells and microorganism, expression vector, process for protein obtaining and remedy containing such a protein
ZA9394B (en) A novel human kunitz-type inhibitor and variants thereof
HK1160778A1 (en) Pharmaceutical composition comprising an analgesic peptide
ATE386118T1 (de) Cnp-gen und vorläuferprotein aus schwein
CA2002924A1 (en) Anti-Thrombins
YU29596A (sh) Genski proizvodi koji regulišu gojaznost
CA2025070A1 (en) Recombinant aprotinin variants genetically engineered process for the microbial preparation of homgeneously processed aprotinin variants and the therapeutic use thereof
AU671989B2 (en) Treatment of tropical spastic paresis with peptide T
CA2196308A1 (en) Peptide, bronchodilator and blood flow ameliorant
ATE124955T1 (de) Substrat-peptide.
AU6354298A (en) Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
HK1013622A1 (en) Pharmaceutical lysine-containing polypeptide compositions and the use thereof
EP0687685A4 (de) Physiologisch-aktive peptide
EP0248231A3 (en) Pharmacologically active peptides
CA2216704A1 (en) Novel peptides and remedy for bone diseases containing the same as active ingredient
RU94046096A (ru) Линейные или циклические пептиды, их применение, способы лечения и конъюгаты пептидов
ATE106088T1 (de) Peptide und deren verwendung in der therapie.
CA2102447A1 (en) Cyclopeptides
RU94036002A (ru) Ингибитор протеазы, днк, вектор, клетка, способ получения ингибитора, фармацевтическая композиция